莫西沙星治疗老年人慢性阻塞性肺疾病急性发作的疗效

    Clinical evaluation of moxifloxacin on acute exacerbation of chronic obstructive pulmonary disease in elderly patients

    • 摘要: 目的:评价莫西沙星治疗老年人慢性阻塞性肺疾病急性发作(AECOPD)的疗效及安全性。方法:将78例AECOPD患者随机分为2组,对照组(38例)予左氧氟沙星0.4g(每天1次),静脉滴注;观察组(40例)予莫西沙星0.4g(每天1次),静脉滴注;2组疗程均为7~14d,观察临床总有效率、细菌清除率及不良反应发生率。结果:观察组总有效率为87.5%,对照组总有效率为73.7%,差异有统计学意义(P0.05)。观察组细菌清除率为90.5%,不良反应发生率为7.5%,对照组细菌清除率为58.8%,不良反应发生率为10.5%,差异均无统计学意义(P0.05)。结论:莫西沙星治疗老年人AECOPD临床疗效肯定。

       

      Abstract: Objective:To evaluate the efficiency and safety of moxifloxacin on acute exacerbation of chronic obstructive pulmonary disease(AECOPD)in elderly patients.Methods:Seventy-eight elderly patients with AECOPD were randomly divided into observation group and control group.In control group,38 patients were treated with levofloxacin at 0.4g,intravenous infusion,one time per day;The 40 patients in observation group were treated with moxifloxacin at 0.4g intravenous infusion,one time per day;the treatment lasted 7-14 days in the two group,the total effective rate、bacterial eradication rate and drug reaction were compared between the two groups.Results:In moxifloxacin group,the effective rate was 87.5%,in levofloxacin group,the effective rate was 73.7%,there had statisticaldifferences(P0.05).The bacterial eradication rate and adverse drug reaction rate were 90.5% and 7.5% in moxifloxacin group vs 58.8% and 10.5% in levofloxacin group,which had no statistical differences(P0.05).Conclusions:Moxifloxacin is an effective and safe drug in treatment of AECOPD in elderly patients.

       

    /

    返回文章
    返回